-
81.发明申请公开(公告)号：US20200085873A1
公开(公告)日：2020-03-19
申请号：US16692035
申请日：2019-11-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , C07K16/24 , A61K39/00 , C07K14/47 , C07K16/28 , A61K39/12 , C07K14/54 , C07K7/06 , A61P35/02 , A61P35/00 , A61K45/06 , C12N5/0783 , A61K39/395 , A61K39/39 , A61K38/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
82.发明申请公开(公告)号：US20200048320A1
公开(公告)日：2020-02-13
申请号：US16591323
申请日：2019-10-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Valentina GOLDFINGER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , C07K7/06 , C07K14/74 , A61K39/00 , C07K16/28 , C07K16/30 , C07K14/725 , C12N15/115 , C12N5/0783 , C12N15/62 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20200024317A1
公开(公告)日：2020-01-23
申请号：US16591158
申请日：2019-10-02
Applicant: Immatics biotechnologies GmbH
Inventor： Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20200002395A1
公开(公告)日：2020-01-02
申请号：US16556693
申请日：2019-08-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
85.发明申请公开(公告)号：US20190375809A1
公开(公告)日：2019-12-12
申请号：US16519959
申请日：2019-07-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Claudia WAGNER , Julia LEIBOLD , Colette SONG
IPC: C07K14/47 , C07K14/725 , A61K35/17 , C07K16/28 , C12N5/0783 , C07K14/74 , A61P35/00 , C07K16/30 , G16B20/20 , G01N33/574 , C12Q1/6886 , A61K39/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
86.发明申请公开(公告)号：US20190330274A1
公开(公告)日：2019-10-31
申请号：US16457012
申请日：2019-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , A61K35/17 , G01N33/68 , C07K16/18 , C12N15/115 , A61K39/00 , C07K14/47 , C07K14/725 , C07K7/06
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
87.发明申请公开(公告)号：US20190314476A1
公开(公告)日：2019-10-17
申请号：US16415671
申请日：2019-05-17
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C07K14/47 , C07K14/725 , C07K14/74 , C12N15/115 , C07K16/28 , C07K16/30 , C07K7/06 , C12N5/0783
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
88.发明申请公开(公告)号：US20190314474A1
公开(公告)日：2019-10-17
申请号：US16415552
申请日：2019-05-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C12N5/0783 , G01N33/574 , C12Q1/6886 , C12N15/115 , C07K14/47 , C07K16/30 , C07K14/74 , C07K14/705 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20190284256A1
公开(公告)日：2019-09-19
申请号：US16425607
申请日：2019-05-29
Applicant: Immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C12N9/12 , C07K14/47 , C07K7/06 , C07K16/28 , C12N15/115 , C12N5/0783 , G01N33/574 , C12Q1/6886 , G01N33/50 , C07K14/725 , C07K16/30 , C07K7/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
90.发明申请公开(公告)号：US20190255110A1
公开(公告)日：2019-08-22
申请号：US16274505
申请日：2019-02-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
612
records
(took 0.062 seconds)
